XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:XBIT
- CUSIP: N/A
- Web: www.xbiotech.com
Capitalization:- Market Cap: $168.68 million
- Outstanding Shares: 35,290,000
Average Prices:- 50 Day Moving Avg: $5.05
- 200 Day Moving Avg: $10.57
- 52 Week Range: $2.77 - $20.18
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.34 per share
- Price / Book: 1.98
Profitability:- EBIDTA: ($51,970,000.00)
- Return on Equity: -71.77%
- Return on Assets: -65.08%
Debt:- Current Ratio: 10.73%
- Quick Ratio: 10.73%
Misc:- Average Volume: 469,095 shs.
- Beta: 0.66
- Short Ratio: 5.75
Frequently Asked Questions for XBiotech (NASDAQ:XBIT)
What is XBiotech's stock symbol?
XBiotech trades on the NASDAQ under the ticker symbol "XBIT."
How were XBiotech's earnings last quarter?
XBiotech Inc. (NASDAQ:XBIT) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.08. View XBiotech's Earnings History.
When will XBiotech make its next earnings announcement?
Where is XBiotech's stock going? Where will XBiotech's stock price be in 2017?
2 equities research analysts have issued 12-month target prices for XBiotech's shares. Their predictions range from $13.00 to $13.00. On average, they anticipate XBiotech's share price to reach $13.00 in the next twelve months. View Analyst Ratings for XBiotech.
Are investors shorting XBiotech?
XBiotech saw a increase in short interest in the month of June. As of June 15th, there was short interest totalling 5,835,997 shares, an increase of 32.2% from the May 31st total of 4,414,704 shares. Based on an average trading volume of 1,692,449 shares, the short-interest ratio is presently 3.4 days. Currently, 37.4% of the shares of the company are sold short.
Who are some of XBiotech's key competitors?
Some companies that are related to XBiotech include Merus N.V. (MRUS), Edge Therapeutics (EDGE), BioTime (BTX), Rigel Pharmaceuticals (RIGL), Corbus Pharmaceuticals Holdings (CRBP), Immune Design Corp. (IMDZ), Minerva Neurosciences (NERV), AVEO Pharmaceuticals (AVEO), Catalyst Pharmaceuticals (CPRX), DURECT Corporation (DRRX), Ardelyx (ARDX), Oxford BioMedica plc (OXB), Circassia Pharmaceuticals PLC (CIR), Stemline Therapeutics (STML), Chimerix (CMRX), Pieris Pharmaceuticals (PIRS), ObsEva SA (OBSV) and Clearside Biomedical (CLSD).
Who are XBiotech's key executives?
XBiotech's management team includes the folowing people:
- John Simard, Chairman of the Board, President, Chief Executive Officer, Founder
- Scott Whitehurst, Chief Financial Officer
- Kelly R. Thornburg, Senior Vice President - Operations
- Queena Han, Vice President - Finance, Human Resources
- David J Combs, Vice President - Manufacturing
- Norma I Gonzalez, Vice President - Quality
- Dawn McCollough, Vice President of Clinical Operations
- Sushma Shivaswamy, Vice President - Research & Development
- Michael D Stecher, Medical Director
- Daniel L. Vasella M.D., Lead Independent Director
When did XBiotech IPO?
(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.
How do I buy XBiotech stock?
Shares of XBiotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is XBiotech's stock price today?
One share of XBiotech stock can currently be purchased for approximately $4.63.
MarketBeat Community Rating for XBiotech (NASDAQ XBIT)MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for XBiotech (NASDAQ:XBIT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $13.00 (180.78% upside) |
Analysts' Ratings History for XBiotech (NASDAQ:XBIT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/3/2017 | Stifel Nicolaus | Upgrade | Hold -> Buy | | High |  |
| 4/21/2017 | Noble Financial | Reiterated Rating | Buy -> Hold | $13.00 | High | |
(Data available from 7/28/2015 forward)
Earnings History for XBiotech (NASDAQ:XBIT)Earnings History by Quarter for XBiotech (NASDAQ XBIT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/14/2017 | | ($0.32) | | | | | N/A | |
| 11/14/2016 | Q3 2016 | ($0.46) | ($0.38) | | | View | Listen | |
| 11/12/2015 | Q3 | ($0.21) | ($0.33) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for XBiotech (NASDAQ:XBIT)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for XBiotech (NASDAQ:XBIT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for XBiotech (NASDAQ:XBIT)Insider Ownership Percentage: 35.70%
Institutional Ownership Percentage: 10.13%
Insider Trades by Quarter for XBiotech (NASDAQ:XBIT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/15/2016 | Queena Han | VP | Sell | 19,573 | $15.00 | $293,595.00 | |
| 9/8/2016 | Queena Han | VP | Sell | 427 | $15.00 | $6,405.00 | |
| 5/26/2016 | W Thorpe Mckenzie | Director | Buy | 20,000 | $13.96 | $279,200.00 | |
| 5/20/2016 | W Thorpe Mckenzie | Director | Buy | 1,500 | $13.75 | $20,625.00 | |
| 12/22/2015 | Queena Han | VP | Sell | 30,000 | $10.39 | $311,700.00 | |
| 11/16/2015 | Michael Stecher | Director | Sell | 1,800 | $14.00 | $25,200.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for XBiotech (NASDAQ:XBIT)
Latest Headlines for XBiotech (NASDAQ:XBIT)
| Source: |
|
| Date | Headline |
|---|
 | Robbins Arroyo LLP: XBiotech Inc. (XBIT) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - July 12 at 9:28 AM |
 | XBiotech Inc. (XBIT) Short Interest Update
www.americanbankingnews.com - June 30 at 7:14 AM |
 | Stock market climbs as health-care shares extend rally
www.marketwatch.com - June 22 at 2:50 PM |
| Today's Research Reports on Stocks to Watch: Xbiotech and GTx
finance.yahoo.com - June 13 at 8:51 AM |
 | Biotech Movers: Coherus, XBiotech, Flexion - TheStreet.com
www.thestreet.com - June 12 at 8:13 PM |
 | BUZZ-US STOCKS ON THE MOVE-GE, tech stocks, Coherus, XBiotech - Nasdaq
www.nasdaq.com - June 12 at 8:13 PM |
| Biotech Movers: Coherus, XBiotech, Flexion
finance.yahoo.com - June 12 at 8:13 PM |
| XBiotech Inc (XBIT) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 10 at 11:12 PM |
| XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis
finance.yahoo.com - June 10 at 3:34 AM |
| Zacks: Analysts Set $10.00 Price Target for XBiotech Inc (XBIT)
www.americanbankingnews.com - June 9 at 8:20 PM |
| XBiotech Inc (XBIT) Expected to Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - June 8 at 7:48 AM |
| Why XBiotech Inc. (XBIT) Could Shock the Market Soon
finance.yahoo.com - June 7 at 1:16 AM |
| XBiotech Inc (XBIT) Rating Increased to Buy at Stifel Nicolaus
www.americanbankingnews.com - June 3 at 10:40 PM |
 | XBiotech (XBIT) Presents Phase III Findings for Antibody Therapy for Colorectal Cancer at ASCO
www.streetinsider.com - June 3 at 2:35 AM |
| Notable Thursday Option Activity: XBIT, BOX, PBYI
www.nasdaq.com - June 3 at 2:35 AM |
| Why XBiotech Inc Jumped Higher Today
finance.yahoo.com - June 3 at 2:35 AM |
| XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
finance.yahoo.com - June 2 at 7:26 AM |
| Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer
finance.yahoo.com - May 30 at 8:08 AM |
| Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Ca...
finance.yahoo.com - May 30 at 8:08 AM |
| XBiotech Inc (XBIT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 20 at 7:08 AM |
| After-Hours Stock Movers 05/18: (SPWH) (ADSK) (MCK) Higher; (XBIT) (HALO) (GSBD) Lower (more...)
www.streetinsider.com - May 19 at 1:52 PM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT
finance.yahoo.com - May 17 at 12:15 AM |
| Zacks: Brokerages Expect XBiotech Inc (XBIT) to Post -$0.47 Earnings Per Share
www.americanbankingnews.com - May 12 at 8:14 AM |
| XBiotech No. 2 Executive Resigns, Leaving Struggling Biotech Without Top Operations Chief
finance.yahoo.com - May 11 at 3:18 PM |
| Edited Transcript of XBIT earnings conference call or presentation 4-May-17 12:30pm GMT
finance.yahoo.com - May 11 at 3:36 AM |
| Investor Network: XBiotech, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 9:29 AM |
| XBiotech (XBIT) Receives Daily News Impact Score of 0.13
www.americanbankingnews.com - May 3 at 4:26 PM |
| XBiotech Inc (XBIT) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - May 2 at 1:52 PM |
| XBiotech to Provide First Quarter 2017 Business Update
finance.yahoo.com - April 29 at 2:40 AM |
| XBiotech (XBIT) Earning Favorable News Coverage, Study Shows
www.americanbankingnews.com - April 28 at 8:34 AM |
| XBiotech (XBIT) Receiving Somewhat Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 25 at 3:14 PM |
| XBiotech Inc (XBIT) Short Interest Update
www.americanbankingnews.com - April 22 at 5:17 PM |
| XBiotech's stock plummets after cancer treatment receives disappointing review panel vote
www.marketwatch.com - April 22 at 9:16 AM |
| XBiotech (XBIT) Announces EMA Negative 'Trend' Vote Related to MAA for Candidate Antibody for Treatment of Colorectal Cancer
www.streetinsider.com - April 22 at 9:16 AM |
| XBiotech Leaves European Meeting 'Disappointed' Over Colon Cancer Drug Rejection
finance.yahoo.com - April 21 at 9:51 PM |
| XBiotech Stock Crumbles Following Disappointing EMA Meeting
finance.yahoo.com - April 21 at 9:51 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
finance.yahoo.com - April 21 at 9:51 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc.
finance.yahoo.com - April 21 at 9:51 PM |
| XBIOTECH NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In XBiotech, Inc. To Contact The Firm
finance.yahoo.com - April 21 at 9:51 PM |
 | Why XBiotech Inc. Got Crushed Today
www.fool.com - April 21 at 2:26 PM |
| XBiotech Inc (XBIT) Stock Rating Lowered by Noble Financial
www.americanbankingnews.com - April 21 at 11:27 AM |
| XBiotech (XBIT) Earning Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 21 at 9:46 AM |
| Zacks: Brokerages Anticipate XBiotech Inc (XBIT) to Post -$0.47 EPS
www.americanbankingnews.com - April 21 at 8:51 AM |
| XBiotech Announces Outcome of EMA's Oral Explanation Meeting
finance.yahoo.com - April 21 at 1:21 AM |
| XBiotech Inc (XBIT) Given $26.00 Consensus Target Price by Analysts
www.americanbankingnews.com - April 20 at 3:20 PM |
 | XBiotech Announces Additions To Its Scientific Advisory Board - GlobeNewswire (press release)
globenewswire.com - April 12 at 8:45 AM |
| XBiotech: Four Staph Patients Died in Our Clinical Trial, Nothing to Worry About
finance.yahoo.com - April 7 at 1:35 PM |
| XBiotech Announces Top-Line Results for 514G3 Antibody Therapy in Serious Staphylococcus aureus Infections
www.nasdaq.com - April 4 at 4:51 AM |
| [video]XBiotech: Four Staph Patients Died in Our Clinical Trial, Nothing to Worry About
www.thestreet.com - April 4 at 4:51 AM |
| Zacks: XBiotech Inc (XBIT) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 4 at 12:43 AM |
XBiotech (XBIT) Chart for Friday, July, 28, 2017
